You are here:
| Reference : Imaging apolipoprotein AI in vivo |
| Scientific journals : Article | |||
| Physical, chemical, mathematical & earth Sciences : Chemistry | |||
| http://hdl.handle.net/2268/102596 | |||
| Imaging apolipoprotein AI in vivo | |
| English | |
| Sriram, Renuka [ > > ] | |
| Lagerstedt, Jens [ > > ] | |
| Petrlova, Jitka [ > > ] | |
| Samardzic, Haris [ > > ] | |
| Kreutzer, Ulrike [ > > ] | |
| Xie, Hongtao [ > > ] | |
| Kaysen, George [ > > ] | |
Desreux, Jean-François  [Université de Liège - ULg > Département de chimie (sciences) > Département de chimie (sciences) >] | |
| Thonon, David [Université de Liège - ULg > > Centre de recherches du cyclotron >] | |
| Jacques, Vincent [ > > ] | |
| Van Loan, M. [ > > ] | |
| Rutledge, J. C. [ > > ] | |
| Oda, M. N. [ > > ] | |
| Voss, John [ > > ] | |
| Jue, T. [ > > ] | |
| 2011 | |
| NMR in Biomedicine | |
| Wiley | |
| 24 | |
| 7 | |
| 916-924 | |
| International | |
| 0952-3480 | |
| Chichester | |
| United Kingdom | |
| [en] Coronary disease risk increases inversely with high-d. lipoprotein (HDL) level. The measurement of the biodistribution
and clearance of HDL in vivo, however, has posed a tech. challenge. This study presents an approach to the development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney, the sites of HDL catabolism, whereas the std. MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acidbismethylamide (GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metab. and regulation in vivo. | |
| http://hdl.handle.net/2268/102596 | |
| 10.1002/nbm.1650 |
| File(s) associated to this reference | ||||||||||||||
|
Fulltext file(s):
| ||||||||||||||
All documents in ORBi are protected by a user license.
